<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37289657</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>23</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>09</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Surveillance To Track Progress Toward Poliomyelitis Eradication - Worldwide, 2021-2022.</ArticleTitle><Pagination><StartPage>613</StartPage><EndPage>620</EndPage><MedlinePgn>613-620</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm7223a1</ELocationID><Abstract><AbstractText>Since the Global Polio Eradication Initiative (GPEI) was established in 1988, the number of wild poliovirus (WPV) cases has declined by &gt;99.9%, and WPV serotypes 2 and 3 have been declared eradicated (1). By the end of 2022, WPV type 1 (WPV1) transmission remained endemic only in Afghanistan and Pakistan (2,3). However, during 2021-2022, Malawi and Mozambique reported nine WPV1 cases that were genetically linked to Pakistan (4,5), and circulating vaccine-derived poliovirus (cVDPV) outbreaks were detected in 42 countries (6). cVDPVs are oral poliovirus vaccine-derived viruses that can emerge after prolonged circulation in populations with low immunity allowing reversion to neurovirulence and can cause paralysis. Polioviruses are detected primarily through surveillance for acute flaccid paralysis (AFP), and poliovirus is confirmed through stool specimen testing. Environmental surveillance, the systematic sampling of sewage and testing for the presence of poliovirus, supplements AFP surveillance. Both surveillance systems were affected by the COVID-19 pandemic's effects on public health activities during 2020 (7,8) but improved in 2021 (9). This report updates previous reports (7,9) to describe surveillance performance during 2021-2022 in 34 priority countries.* In 2022, a total of 26 (76.5%) priority countries met the two key AFP surveillance performance indicator targets nationally compared with 24 (70.6%) countries in 2021; however, substantial gaps remain in subnational areas. Environmental surveillance expanded to 725 sites in priority countries, a 31.1% increase from the 553 sites reported in 2021. High-quality surveillance is critical to rapidly detect poliovirus transmission and enable prompt poliovirus outbreak response to stop circulation. Frequent monitoring of surveillance guides improvements to achieve progress toward polio eradication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stehling-Ariza</LastName><ForeName>Tasha</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Amanda L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Diop</LastName><ForeName>Ousmane M</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>Jorba</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Asghar</LastName><ForeName>Humayun</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Avagnan</LastName><ForeName>Tigran</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Grabovac</LastName><ForeName>Varja</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Ticha</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Sudhir</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kfutwah</LastName><ForeName>Anfumbom K W</ForeName><Initials>AKW</Initials></Author><Author ValidYN="Y"><LastName>Sangal</LastName><ForeName>Lucky</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sharif</LastName><ForeName>Salmaan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wahdan</LastName><ForeName>Ashraf</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tallis</LastName><ForeName>Graham F</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Stephanie D</ForeName><Initials>SD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000509">alpha-Fetoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000509" MajorTopicYN="N">alpha-Fetoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>8</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>8</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37289657</ArticleId><ArticleId IdType="pmc">PMC10328463</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7223a1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rachlin A, Patel JC, Burns CC, et al. Progress toward polio eradication—worldwide, January 2020–April 2022. MMWR Morb Mortal Wkly Rep 2022;71:650–5. 10.15585/mmwr.mm7119a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7119a2</ArticleId><ArticleId IdType="pmc">PMC9098249</ArticleId><ArticleId IdType="pubmed">35552352</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed A, Akbar IE, Chaudhury S, et al. Progress toward poliomyelitis eradication—Afghanistan, January 2021–September 2022. MMWR Morb Mortal Wkly Rep 2022;71:1541–6. 10.15585/mmwr.mm7149a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7149a1</ArticleId><ArticleId IdType="pmc">PMC9762895</ArticleId><ArticleId IdType="pubmed">36480464</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbaeyi C, Baig S, Safdar MR, et al. Progress toward poliomyelitis eradication—Pakistan, January 2021–July 2022. MMWR Morb Mortal Wkly Rep 2022;71:1313–8. 10.15585/mmwr.mm7142a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7142a1</ArticleId><ArticleId IdType="pmc">PMC9590290</ArticleId><ArticleId IdType="pubmed">36264783</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. Malawi. Geneva, Switzerland: Global Polio Eradication Initiative; 2022. https://polioeradication.org/where-we-work/malawi</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Mozambique. Geneva, Switzerland: Global Polio Eradication Initiative; 2022. https://polioeradication.org/where-we-work/Mozambique</Citation></Reference><Reference><Citation>Bigouette JP, Henderson E, Traoré MA, et al. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2021–December 2022. MMWR Morb Mortal Wkly Rep 2023;72:366–71. 10.15585/mmwr.mm7214a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7214a3</ArticleId><ArticleId IdType="pmc">PMC10078846</ArticleId><ArticleId IdType="pubmed">37022974</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuma JN, Wilkinson AL, Diop OM, et al. Surveillance to track progress toward polio eradication—worldwide, 2019–2020. MMWR Morb Mortal Wkly Rep 2021;70:667–73. 10.15585/mmwr.mm7018a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7018a2</ArticleId><ArticleId IdType="pmc">PMC9368747</ArticleId><ArticleId IdType="pubmed">33956779</ArticleId></ArticleIdList></Reference><Reference><Citation>Zomahoun DJ, Burman AL, Snider CJ, et al. Impact of COVID-19 pandemic on global poliovirus surveillance. MMWR Morb Mortal Wkly Rep 2021;69:1648–52. 10.15585/mmwr.mm695152a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm695152a4</ArticleId><ArticleId IdType="pmc">PMC9191906</ArticleId><ArticleId IdType="pubmed">33382673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson AL, Diop OM, Jorba J, Gardner T, Snider CJ, Ahmed J. Surveillance to track progress toward polio eradication—worldwide, 2020–2021. MMWR Morb Mortal Wkly Rep 2022;71:538–44. 10.15585/mmwr.mm7115a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7115a2</ArticleId><ArticleId IdType="pmc">PMC9020859</ArticleId><ArticleId IdType="pubmed">35421079</ArticleId></ArticleIdList></Reference><Reference><Citation>Diop OM, Kew OM, de Gourville EM, Pallansch MA. The Global Polio Laboratory Network as a platform for the viral vaccine-preventable and emerging diseases laboratory networks. J Infect Dis 2017;216(Suppl 1):S299–307. 10.1093/infdis/jix092</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix092</ArticleId><ArticleId IdType="pmc">PMC5853949</ArticleId><ArticleId IdType="pubmed">28838192</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>